GEN Exclusives

More »

GEN News Highlights

More »
Aug 2, 2012

Covidien Opens $45M R&D Facility in Shanghai

  • Covidien opened its China Technology Center (CTC) R&D facility in Shanghai, with a total investment of $45 million over a three-year period. The facility spans more than 100,000 square feet (9,290 square meters), houses 17 laboratories, and has state-of-the-art surgical and simulation suites that enable healthcare professionals to be actively involved in the medical device design and development process.

    The CTC has two core focus areas: design of tailored products, to identify and develop products that are customized to meet the needs of China and other emerging markets; and discovery of breakthrough platforms in medical technology, to utilize the skill sets and expertise of employees in Asia.

    “By collaborating closely with local medical experts who use our products, we can tailor devices to meet the demands of China and other emerging markets,” says Dong Wu, vp, China R&D, Covidien. “We are dedicated to improving patient outcomes, and we recognize the immense potential of basing an R&D facility in Shanghai. This location will help us tap into internationally renowned experts based here in China, including world-class engineering talent. We believe this collaboration will drive innovation in China and across the emerging markets healthcare landscape.”

    Covidien already has 10 commercial offices, a manufacturing center, and training facilities for healthcare professionals in China.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?